MISTI’s pulmonary drug delivery applications begin with respiratory care and may extend across pharmaceutical development, healthcare systems, public health and future field based healthcare.
Each setting brings different pressures.
Pharmaceutical teams are working with more complex medicines. Healthcare providers are managing respiratory care beyond the clinic. Public health and government partners are looking for scalable ways to support access, preparedness and system resilience. Field based care environments need systems that can work when conditions are not ideal.
But across every setting, the core questions remain similar.
Can medicine reach the lungs reliably?
Can delivery work with real breathing behaviour?
Can the system support sensitive formulations?
Can care teams see what happened?
MISTI® is being developed around these shared delivery challenges.
How could MISTI® support pharmaceutical development?
For pharmaceutical and biotech teams, delivery can shape whether a therapy moves from promising formulation to practical pulmonary pathway.
Advanced medicines may need gentler aerosolisation, stronger particle control and delivery systems that preserve formulation integrity. MISTI’s mesh free acoustic delivery approach is being developed to support these requirements and create future opportunities for pulmonary drug delivery co development.
Potential relevance includes:
When respiratory treatment moves into the home, visibility drops.
Patients manage inhaled therapy between appointments, after discharge, in aged care, in community settings and under caregiver support.
But clinicians may not know whether treatment was completed, whether the patient struggled with the device, or whether delivery timing affected the outcome.
Potential relevance includes:
For public health teams, better delivery can support access,
resilience and care outside overloaded hospital systems.
Respiratory illness can place pressure on hospitals, clinics, families and public health budgets.
Government and health system partners are often focused on preserving hospital capacity, improving access to care, supporting remote communities, reducing avoidable escalation and strengthening preparedness.
The question is not only how to treat more people.
It is how to support care can be done earlier, closer to home and with better visibility.
Potential relevance includes:
This is where pulmonary delivery becomes part of a broader system conversation.
Not all care happens in controlled environments.
Emergency and field care are future facing pathways for MISTI®, but they reflect an important design direction: Respiratory delivery needs to be practical beyond controlled clinical environments.
Remote communities, field hospitals, emergency response settings and defence health environments may require delivery systems that are portable, practical and easy to use under pressure.
Potential relevance includes:
This pathway is future facing, but it reflects why portability, usability and
deployment readiness matter in MISTI’s broader delivery approach.
MedMISTI™ gives MISTI® a focused first use case: respiratory care, where delivery success depends on timing, usability and confidence outside the clinic.
It applies MISTI’s core delivery principles to a real world problem: helping patients receive inhaled therapy in a way that is more usable, more consistent and better aligned to natural breathing behaviour.
MedMISTI™ helps demonstrate the platform’s core principles:
The first application matters because it gives MISTI® a practical pathway to demonstrate value before expanding into broader applications.
From MedMISTI™, the same delivery principles may inform future pathways across pharmaceutical development, healthcare systems, public health and field based care.
Across every pathway, MISTI® is being developed around the same core questions:
That is what makes MISTI® more than a single application. It is a platform designed around a shared delivery problem.
If your organisation is exploring respiratory medicines, advanced therapeutics, connected care or scalable health deployment, MISTI® offers a new pulmonary delivery pathway worth exploring.
The first application is MedMISTI™.
The broader opportunity is a platform designed for the places where better delivery can change what is possible.
Find answers about how MedMISTI™ works and what it can do for you
MISTI® is being developed with potential application pathways across respiratory care, pharmaceutical development, healthcare systems, public health, government and future field based healthcare settings.
MISTI’s first real world application is MedMISTI™, which focuses on respiratory care. It gives the platform a focused starting point where usability, timing, adherence and delivery visibility are critical.
MedMISTI™ applies MISTI’s core delivery principles in respiratory care. Those same principles, including breath actuated delivery, mesh free aerosol generation and connected visibility, may support future applications across pharmaceutical development, public health and field based care.
MISTI® may support pharmaceutical and biotech partners exploring pulmonary delivery for biologics, RNA based medicines, inhaled vaccines and other complex formulations. Co-development opportunities may include formulation fit, aerosol performance, device integration and delivery pathway planning.
MISTI® may support healthcare systems by helping make inhaled therapy easier to complete, easier to monitor and better suited to patients receiving care at home, in aged care, in community settings or between clinical appointments.
MISTI® may have future relevance for public health pathways that require scalable respiratory care, home based treatment models, remote support, connected care visibility and preparedness for respiratory health pressures.
Emergency and field use applications are future facing pathways. They reflect MISTI’s broader platform potential in settings where portability, usability, rapid deployment and respiratory support may matter.
